Non-tuberculous mycobacteria, or NTM, are a group of bacteria that cause rare lung infections. NTM can cause health problems for people with no pre-existing condition, but it’s more likely to affect people with an underlying lung problem, such as bronchiectasis, cystic fibrosis, COPD or pulmonary fibrosis. The symptoms are similar to other lung infections and can include: cough, fever, tiredness and losing weight. [1]
More information on NTMs can be found here: https://www.ntmpatientcare.uk/
ENCORE is a study looking at a new treatment for patients with NTM caused by Mycobacterium avium Complex (MAC). There are research sites all over the world, one of them in Aberdeen Royal Infirmary. Dr Brittain-Long, Infectious disease consultant, is leading the local study team. He said: “We have had a dedicated NTM service running since 2017 and have seen an increasing number of referrals year on year. There is a definite and global need for more effective and safe treatment options for our patients with NTM disease, and we welcomed the ENCORE trial at an early stage. Our team are committed and happy to contributing to this important study.” The team has recruited 3 volunteers to take part in the study so far. More information about the study can be found here:
Study Details | Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex | ClinicalTrials.gov
Running clinical trials requires team work and specialist knowledge. Research nurses, clinical trials pharmacists working alongside doctors, lab technicians and others to identify eligible patients and care for patients taking part in clinical trials. Every staff member undergoes specialist study specific training before the study can start.
[1] https://www.asthmaandlung.org.uk/conditions/non-tuberculous-mycobacterial-infection-ntm